PortalPublikationenPopulation pharmacokinetics of vancomycin in critically ill ...

Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy

Standard

Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. / Economou, Caleb J P; Kielstein, Jan T; Czock, David; Xie, Jiao; Field, Jonathan; Richards, Brent; Tallot, Mandy; Visser, Adam; Koenig, Christina; Hafer, Carsten; Schmidt, Julius J; Lipman, Jeffrey; Roberts, Jason A.

in: INT J ANTIMICROB AG, Jahrgang 52, Nr. 2, 08.2018, S. 151-157.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Economou, CJP, Kielstein, JT, Czock, D, Xie, J, Field, J, Richards, B, Tallot, M, Visser, A, Koenig, C, Hafer, C, Schmidt, JJ, Lipman, J & Roberts, JA 2018, 'Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy', INT J ANTIMICROB AG, Jg. 52, Nr. 2, S. 151-157. https://doi.org/10.1016/j.ijantimicag.2018.03.001

APA

Economou, C. J. P., Kielstein, J. T., Czock, D., Xie, J., Field, J., Richards, B., Tallot, M., Visser, A., Koenig, C., Hafer, C., Schmidt, J. J., Lipman, J., & Roberts, J. A. (2018). Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. INT J ANTIMICROB AG, 52(2), 151-157. https://doi.org/10.1016/j.ijantimicag.2018.03.001

Vancouver

Economou CJP, Kielstein JT, Czock D, Xie J, Field J, Richards B et al. Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy. INT J ANTIMICROB AG. 2018 Aug;52(2):151-157. https://doi.org/10.1016/j.ijantimicag.2018.03.001

Bibtex

@article{44970b1902e549d6a314469daf7f6263,
title = "Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy",
abstract = "OBJECTIVES: The aim of this study was to describe the population pharmacokinetics of vancomycin during prolonged intermittent renal replacement therapy (PIRRT) in critically ill patients with acute kidney injury.METHODS: Critically ill patients prescribed vancomycin across two sites had blood samples collected during one to three dosing intervals during which PIRRT was performed. Plasma samples were assayed with a validated immunoassay method. Population pharmacokinetic analysis and Monte Carlo simulations were performed using Pmetrics{\textregistered}. The target vancomycin exposures were the area under the concentration-time curve within a 24-h period (AUC0-24)/minimum inhibitory concentration (MIC) ratio of 400 for efficacy and AUC0-24 700 for toxicity.RESULTS: Eleven critically ill patients (seven male) were enrolled and contributed 192 plasma samples. The patient's mean ± standard deviation (SD) age, weight and body mass index (BMI) were 57 ± 13 years, 98 ± 43 kg and 31 ± 9 kg/m2, respectively. A two-compartment linear model adequately described the data. The mean ± SD population pharmacokinetic parameter estimates were PIRRT clearance (CL) 3.47 ± 1.99 L/h, non-PIRRT CL 2.15 ± 2.07 L/h, volume of distribution of the central compartment (Vc) 41.85 ± 24.33 L, distribution rate constant from central to peripheral compartment 5.97 ± 7.93 per h and from peripheral to central compartment 5.29 ± 6.65 per h. Assuming a MIC of 1 mg/L, vancomycin doses of 25 mg/kg per day are suggested to be efficacious, whilst minimising toxic, exposures.CONCLUSIONS: This is the first population pharmacokinetic study of vancomycin in patients receiving PIRRT and we observed large pharmacokinetic variability. Empirically, weight-based doses that are appropriate for the duration of PIRRT, should be selected and supplemented with therapeutic drug monitoring.",
keywords = "Journal Article",
author = "Economou, {Caleb J P} and Kielstein, {Jan T} and David Czock and Jiao Xie and Jonathan Field and Brent Richards and Mandy Tallot and Adam Visser and Christina Koenig and Carsten Hafer and Schmidt, {Julius J} and Jeffrey Lipman and Roberts, {Jason A}",
note = "Copyright {\textcopyright} 2018. Published by Elsevier B.V.",
year = "2018",
month = aug,
doi = "10.1016/j.ijantimicag.2018.03.001",
language = "English",
volume = "52",
pages = "151--157",
journal = "INT J ANTIMICROB AG",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Population pharmacokinetics of vancomycin in critically ill patients receiving prolonged intermittent renal replacement therapy

AU - Economou, Caleb J P

AU - Kielstein, Jan T

AU - Czock, David

AU - Xie, Jiao

AU - Field, Jonathan

AU - Richards, Brent

AU - Tallot, Mandy

AU - Visser, Adam

AU - Koenig, Christina

AU - Hafer, Carsten

AU - Schmidt, Julius J

AU - Lipman, Jeffrey

AU - Roberts, Jason A

N1 - Copyright © 2018. Published by Elsevier B.V.

PY - 2018/8

Y1 - 2018/8

N2 - OBJECTIVES: The aim of this study was to describe the population pharmacokinetics of vancomycin during prolonged intermittent renal replacement therapy (PIRRT) in critically ill patients with acute kidney injury.METHODS: Critically ill patients prescribed vancomycin across two sites had blood samples collected during one to three dosing intervals during which PIRRT was performed. Plasma samples were assayed with a validated immunoassay method. Population pharmacokinetic analysis and Monte Carlo simulations were performed using Pmetrics®. The target vancomycin exposures were the area under the concentration-time curve within a 24-h period (AUC0-24)/minimum inhibitory concentration (MIC) ratio of 400 for efficacy and AUC0-24 700 for toxicity.RESULTS: Eleven critically ill patients (seven male) were enrolled and contributed 192 plasma samples. The patient's mean ± standard deviation (SD) age, weight and body mass index (BMI) were 57 ± 13 years, 98 ± 43 kg and 31 ± 9 kg/m2, respectively. A two-compartment linear model adequately described the data. The mean ± SD population pharmacokinetic parameter estimates were PIRRT clearance (CL) 3.47 ± 1.99 L/h, non-PIRRT CL 2.15 ± 2.07 L/h, volume of distribution of the central compartment (Vc) 41.85 ± 24.33 L, distribution rate constant from central to peripheral compartment 5.97 ± 7.93 per h and from peripheral to central compartment 5.29 ± 6.65 per h. Assuming a MIC of 1 mg/L, vancomycin doses of 25 mg/kg per day are suggested to be efficacious, whilst minimising toxic, exposures.CONCLUSIONS: This is the first population pharmacokinetic study of vancomycin in patients receiving PIRRT and we observed large pharmacokinetic variability. Empirically, weight-based doses that are appropriate for the duration of PIRRT, should be selected and supplemented with therapeutic drug monitoring.

AB - OBJECTIVES: The aim of this study was to describe the population pharmacokinetics of vancomycin during prolonged intermittent renal replacement therapy (PIRRT) in critically ill patients with acute kidney injury.METHODS: Critically ill patients prescribed vancomycin across two sites had blood samples collected during one to three dosing intervals during which PIRRT was performed. Plasma samples were assayed with a validated immunoassay method. Population pharmacokinetic analysis and Monte Carlo simulations were performed using Pmetrics®. The target vancomycin exposures were the area under the concentration-time curve within a 24-h period (AUC0-24)/minimum inhibitory concentration (MIC) ratio of 400 for efficacy and AUC0-24 700 for toxicity.RESULTS: Eleven critically ill patients (seven male) were enrolled and contributed 192 plasma samples. The patient's mean ± standard deviation (SD) age, weight and body mass index (BMI) were 57 ± 13 years, 98 ± 43 kg and 31 ± 9 kg/m2, respectively. A two-compartment linear model adequately described the data. The mean ± SD population pharmacokinetic parameter estimates were PIRRT clearance (CL) 3.47 ± 1.99 L/h, non-PIRRT CL 2.15 ± 2.07 L/h, volume of distribution of the central compartment (Vc) 41.85 ± 24.33 L, distribution rate constant from central to peripheral compartment 5.97 ± 7.93 per h and from peripheral to central compartment 5.29 ± 6.65 per h. Assuming a MIC of 1 mg/L, vancomycin doses of 25 mg/kg per day are suggested to be efficacious, whilst minimising toxic, exposures.CONCLUSIONS: This is the first population pharmacokinetic study of vancomycin in patients receiving PIRRT and we observed large pharmacokinetic variability. Empirically, weight-based doses that are appropriate for the duration of PIRRT, should be selected and supplemented with therapeutic drug monitoring.

KW - Journal Article

U2 - 10.1016/j.ijantimicag.2018.03.001

DO - 10.1016/j.ijantimicag.2018.03.001

M3 - SCORING: Journal article

C2 - 29526606

VL - 52

SP - 151

EP - 157

JO - INT J ANTIMICROB AG

JF - INT J ANTIMICROB AG

SN - 0924-8579

IS - 2

ER -